Raymond James & Associates’s Acer Therapeutics Inc ACER Stock Holding History

Raymond James & Associates’s Portfolio ACER Stock Details ACER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-16,200	Closed	-$37K	–	4315
2021 Q4	$37K	Hold	16,200	–	–	﹤0.01%	3983
2021 Q3	$41K	Hold	16,200	–	–	﹤0.01%	3933
2021 Q2	$46K	Hold	16,200	–	–	﹤0.01%	3922
2021 Q1	$50K	Hold	16,200	–	–	﹤0.01%	3855
2020 Q4	$42K	Hold	16,200	–	–	﹤0.01%	3638
2020 Q3	$47K	Hold	16,200	–	–	﹤0.01%	3454
2020 Q2	$56K	Hold	16,200	–	–	﹤0.01%	3367
2020 Q1	$32K	Sell	16,200 -500	-3%	-$1.83K	﹤0.01%	3360
2019 Q4	$67K	Hold	16,700	–	–	﹤0.01%	3525
2019 Q3	$53K	Sell	16,700 -146,632	-90%	-$430K	﹤0.01%	3463
2019 Q2	$637K	Buy	163,332 +111,410	+215%	+$2.12M	﹤0.01%	2502
2019 Q1	$1.26M	Buy	+51,922	New	+$1.23M	﹤0.01%	2059

Other funds holding ACER

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

LFG

Larson Financial Group St Louis, Missouri $3.81B AUM 32.31% 1-Year Est. Return

Raymond James & Associates's ACER Position: Q1 2022 in Review

Raymond James & Associates sold out of Acer Therapeutics Inc (ACER) in Q1 2022, closing a stake of 16,200 shares — an estimated $37K sold.

Raymond James & Associates first reported a position in ACER in Q1 2019 and held it in 12 quarters. The position peaked at $1.26M in Q1 2019. 21 funds tracked by Wall St. Rank hold ACER as of Q1 2022.

Raymond James & Associates reported no remaining Acer Therapeutics Inc position as of Q1 2022 after selling out during the quarter.
Raymond James & Associates sold 16,200 Acer Therapeutics Inc shares in Q1 2022, an estimated $37K.
Raymond James & Associates first reported a position in Acer Therapeutics Inc in Q1 2019 and held it in 12 quarters.
Raymond James & Associates's Acer Therapeutics Inc position peaked at $1.26M in Q1 2019.
21 funds tracked by Wall St. Rank held Acer Therapeutics Inc as of Q1 2022.

Based on Raymond James & Associates's 13F filing for Q1 2022, filed 11 May 2022.